TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG Therapeutics, Inc. Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60…
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
TG Therapeutics, Inc. 82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement…